ONCOCHECK
A simple blood test for prognosis and monitoring of patients undergoing cancer therapy.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ONCOCHECK project word cloud
Explore the words cloud of the ONCOCHECK project. It provides you a very rough idea of what is the project "ONCOCHECK" about.
Project "ONCOCHECK" data sheet
The following table provides information about the project.
| Coordinator |
LIFE LENGTH SL
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.oncocheck.eu/ |
| Total cost | 3˙109˙948 € |
| EC max contribution | 3˙109˙948 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-01-01 to 2018-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | LIFE LENGTH SL | ES (MADRID) | coordinator | 3˙109˙948.00 |
Map
Project objective
The objective of the ONCOCHECK project is to bring to the healthcare market a unique solution for cancer prognosis and monitoring which is a simple and inexpensive (<€200/test) blood test that will allow oncologists the prediction and evaluation of disease progression (monitoring) in patients affected by the great majority of cancers, with no distinction between haematological or solid tumors. The ONCOCHECK test is based on the determination of telomere length in peripheral blood, which is a blood cell marker that has been identified in the majority of cancers. The great advantage of the ONCOCHECK tests over any competing blood tests based on cancer tumor markers is that ONCOCHECK will serve for monitoring virtually all types of cancer, while competing tumor marker based solutions are useful only for a specific cancer/tumor. Therefore, Life Length´s test will offer a universal solution for cancer monitoring, with no competitors offering a similar approach. Considering the more than 35 million of people affected by cancer all over the world and that ONCOCHECK will serve for monitoring all cancer types, the business opportunity seems unquestionable. Through the ONCOCHECK project, we seek positioning our company as a leading player in the Advanced Next Generation Cancer Diagnostic Market, which was already estimated globally to generate €7.1 billion in sales in 2015 and is forecast to exceed €13.1 billion by 2020. The main market drivers are the development of less invasive and less costly tools that can contribute to a more efficient, more frequent and sustainable management of cancer. In line with this, the ONCOCHECK project will offer oncologist a cost effective solution to the current challenges in regular cancer monitoring and management.
Deliverables
| ONCOCHECK webpage. | Websites, patent fillings, videos etc. | 2019-07-18 22:20:30 |
Take a look to the deliverables list in detail: detailed list of ONCOCHECK deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
J.A GarcÃa-Marco1, A. Alegre2, P Baltasar3, J Loscertales2, J.A. Hernández Rivas4, R MartÃnez5, P Sánchez Godoy6, J. de la Serna7, J.A. GarcÃa-Vela8, Laura Esteban9, Nuria de Pedro10, Irene GarcÃa10, Lissette Otero10, Juan Estrada10, Jorge GarcÃa10, MarÃa Diez10, Rut González10, Beatriz GarcÃa10, Rafael Higuera11, Enrique Segovia11, Luis Fernández11 and Pilar Najarro9. On behalf of GMCLL Estudio de validación clÃnica de las variables a los telómeros como biomarcadores pronóstico en LLC published pages: PC-143 Abstract,, ISSN: , DOI: |
Published during the SEHH annual congress (http://www.sehhseth.es/es/) | 2019-07-18 |
| 2017 |
Pilar Najarro (Life Length Scientific Director & COO) Outrunning ageing and cancer published pages: 180-181, ISSN: , DOI: |
Horizon 2020 Projects: Portal | 2019-07-18 |
| 2017 |
N. De Pedro, J.C. Estrada , M. Chiesa, M. Diez , I. Garcia , R. Gonzalez , B. Garcia , J. Garcıa , L. Esteban , L. Otero , P. Najarro Telomere associated variables and their potential in CLL prognosis published pages: (Abstract 98P, p, ISSN: , DOI: |
ESMO Annals of Oncology (Abstract Book) Abstract Book of the 42nd ESMO | 2019-07-18 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOCHECK" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCOCHECK" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
LEGACy (2019)
CeLac and European consortium for a personalized medicine approach to Gastric Cancer
Read MoreRESHAPE (2019)
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More